发明授权
US09493567B2 Methods of treating inflammatory and autoimmune diseases with natalizumab
有权
用那他珠单抗治疗炎症和自身免疫性疾病的方法
- 专利标题： Methods of treating inflammatory and autoimmune diseases with natalizumab
- 专利标题（中）： 用那他珠单抗治疗炎症和自身免疫性疾病的方法
-
申请号： US12757305申请日： 2010-04-09
-
公开(公告)号： US09493567B2公开(公告)日： 2016-11-15
- 发明人: Ivan Lieberburg
- 申请人： Ivan Lieberburg
- 申请人地址： US MA Cambridge
- 专利权人： Biogen Inc.
- 当前专利权人： Biogen Inc.
- 当前专利权人地址： US MA Cambridge
- 代理机构： Arnold & Porter LLP
- 代理商 Nathan Edwards; Ginger R. Dreger
- 主分类号： A61K39/395
- IPC分类号： A61K39/395 ; C07K16/28 ; G01N33/68 ; A61K39/00
摘要：
Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy.
公开/授权文献
信息查询
